1921
Volume 89, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

To assess the spectrum of illness from toxigenic O1 and risk factors for severe cholera in Haiti, we conducted a cross-sectional survey in a rural commune with more than 21,000 residents. During March 22–April 6, 2011, we interviewed 2,622 residents ≥ 2 years of age and tested serum specimens from 2,527 (96%) participants for vibriocidal and antibodies against cholera toxin; 18% of participants reported a cholera diagnosis, 39% had vibriocidal titers ≥ 320, and 64% had vibriocidal titers ≥ 80, suggesting widespread infection. Among seropositive participants (vibriocidal titers ≥ 320), 74.5% reported no diarrhea and 9.0% had severe cholera (reported receiving intravenous fluids and overnight hospitalization). This high burden of severe cholera is likely explained by the lack of pre-existing immunity in this population, although the virulence of the atypical El Tor strain causing the epidemic and other factors might also play a role.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.13-0208
2013-10-09
2017-11-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/89/4/654.html?itemId=/content/journals/10.4269/ajtmh.13-0208&mimeType=html&fmt=ahah

References

  1. Jenson D, Szabo V, , 2011. Cholera in Haiti and other Caribbean regions, 19th century. Emerg Infect Dis 17: 21302135.[Crossref]
  2. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, Mintz ED, Steenland MW, Vertefeuille JF, Tappero JW, , 2013. Cholera surveillance during the Haiti epidemic: the first 2 years. N Engl J Med 368: 599609.[Crossref]
  3. Ministère de la Santé Publique et de la Population, 2013. MSPP Daily Reports on the Cholera Epidemic in Haiti [Rapports Journaliers du MSPP sur l'Évolution du Choléra en Haiti]. Available at: http://www.mspp.gouv.ht/site/index.php?option=com_content&view=article&id=120&Itemid=1. Accessed April 8, 2013.
  4. Swerdlow DL, Ries AA, , 1992. Cholera in the Americas: guidelines for the clinician. JAMA 267: 14951499.[Crossref]
  5. Bart KJ, Huq Z, Khan M, Mosley WH, , 1970. Seroepidemiologic studies during a simultaneous epidemic of infection with El Tor Ogawa and classical Inaba Vibrio cholerae . J Infect Dis 121 (Suppl): S17S24.[Crossref]
  6. Woodward WE, Mosley WH, McCormack WM, , 1970. The spectrum of cholera in rural East Pakistan. I. Correlation of bacteriologic and serologic results. J Infect Dis 121 (Suppl): S10S16.[Crossref]
  7. Gangarosa EJ, Mosley WH, Barua D, Burrows W, , 1974. Epidemiology and surveillance of cholera. , eds. Cholera. Philadelphia, PA: WB Saunders Co, 381403.
  8. Safa A, Nair GB, Kong RY, , 2010. Evolution of new variants of Vibrio cholerae O1. Trends Microbiol 18: 4654.[Crossref]
  9. Talkington D, Bopp C, Tarr C, Parsons MB, Dahourou G, Freeman M, Joyce K, Turnsek M, Garrett N, Humphrys M, Gomez G, Stroika S, Boncy J, Ochieng B, Oundo J, Klena J, Smith A, Keddy K, Gerner-Smidt P, , 2011. Characterization of toxigenic Vibrio cholerae from Haiti, 2010–2011. Emerg Infect Dis 17: 21222129.[Crossref]
  10. Ghosh-Banerjee J, Senoh M, Takahashi T, Hamabata T, Barman S, Koley H, Mukhopadhyay AK, Ramamurthy T, Chatterjee S, Asakura M, Yamasaki S, Nair GB, Takeda Y, , 2010. Cholera toxin production by El Tor variant of Vibrio cholerae O1 as compared to prototype El Tor and classical biotypes. J Clin Microbiol 48: 42834286.[Crossref]
  11. Siddique AK, Nair GB, Alam M, Sack DA, Huq A, Nizam A, Longini IM, Jr Qadri F, Faruque SM, Colwell RR, Ahmed S, Iqbal A, Bhuiyan NA, Sack RB, , 2010. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 138: 347352.[Crossref]
  12. Harris JB, LaRocque RC, Chowdhury F, Khan AI, Logvinenko T, Faruque AS, Ryan ET, Qadri F, Calderwood SB, , 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis 2: e221.[Crossref]
  13. Glass RI, Holmgren J, Haley CE, Khan MR, Svennerholm AM, Stoll BJ, Belayet Hossain KM, Black RE, Yunus M, Barua D, , 1985. Predisposition for cholera of individuals with O blood group: possible evolutionary significance. Am J Epidemiol 121: 791796.[Crossref]
  14. Swerdlow DL, Mintz ED, Rodriguez M, Tejada E, Ocampo C, Espejo L, Barrett TJ, Petzelt J, Bean NH, Seminario L, Tauxe RV, , 1994. Severe life-threatening cholera associated with blood group O in Peru: implications for the Latin American epidemic. J Infect Dis 170: 468472.[Crossref]
  15. Harris JB, Khan AI, LaRocque RC, Dorer DJ, Chowdhury F, Faruque ASG, Sack DA, Ryan ET, Qadri F, Calderwood SB, , 2005. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 73: 74227427.[Crossref]
  16. Cserti CM, Dzik WH, , 2007. The ABO blood group system and Plasmodium falciparum malaria. Blood 110: 22502258.[Crossref]
  17. Nalin DR, Levine RJ, Levine MM, Hoover D, Bergquist E, McLaughlin J, Libonati J, Alam J, Hornick RB, , 1978. Cholera, non-vibrio cholera, and stomach acid. Lancet 312: 856859.[Crossref]
  18. Van Loon FPL, Clemens JD, Shahrier M, Sack DA, Stephensen CB, Khan MR, Rabbani GH, Rao MR, Banik AK, , 1990. Low gastric acid as a rise factor for cholera transmission: application of a new non-invasive gastric acid field test. J Clin Epidemiol 43: 13611367.[Crossref]
  19. Alam AN, Goff PA, Abdal NM, Rashid MA, Rahaman MM, , 1991. Serum ferritin and cholera: a prospective study. Trop Geogr Med 43: 1216.
  20. Steinberg EB, Greene KD, Bopp CA, Cameron DN, Wells JG, Mintz ED, , 2001. Cholera in the United States, 1995–2000: trends at the end of the twentieth century. J Infect Dis 184: 799802.[Crossref]
  21. Glass RI, Svennerholm AM, Khan MR, Huda S, Huq MI, Holmgren J, , 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151: 236242.[Crossref]
  22. Clements ML, Levine MM, Young CR, Black RE, Lim YL, Robins-Browne RM, Craig JP, , 1982. Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae . J Infect Dis 145: 465473.[Crossref]
  23. Levine MM, Young CR, Hughes TP, O'Donnell S, Black RE, Clements ML, Robins-Browne R, Lim YL, , 1981. Duration of serum antitoxin response following Vibrio cholerae infection in North Americans: relevance for seroepidemiology. Am J Epidemiol 114: 348354.[Crossref]
  24. Harris AM, Bhuiyan MS, Chowdhury F, Khan AI, Hossain A, Kendall EA, Rahman A, LaRocque RC, Wrammert J, Ryan ET, Qadri F, Calderwood SB, Harris JB, , 2009. Antigen specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun 77: 38503856.[Crossref]
  25. Piarroux R, Barrais R, Faucher B, Haus R, Piarroux M, Gaudart J, Magloire R, Raoult D, , 2011. Understanding the cholera epidemic, Haiti. Emerg Infect Dis 17: 11611168.[Crossref]
  26. Institut Haitien de Statistique et d'Informatique, 2009. Estimate of Total Population and 18 Years and Older for the Year 2009 [Estimation pour l'Année 2009 des Populations Totale et de 18 Ans et Plus]. Available at: http://www.ihsi.ht/pdf/projection/POPTOTAL&MENAGDENS_ESTIM2009.pdf. Accessed April 8, 2013.
  27. Reimer AR, Van Domselaar G, Stroika S, Walker M, Kent H, Tarr C, Talkington D, Rowe L, Olsen-Rasmussen M, Frace M, Sammons S, Dahourou GA, Boncy J, Smith AM, Mabon P, Petkau A, Graham M, Gilmour MW, Gerner-Smidt P, , 2011. Comparative genomics of Vibrio cholerae from Haiti, Asia, and Africa. Emerg Infect Dis 17: 21132121.[Crossref]
  28. Centers for Disease Control and Prevention, 2012. Notes from the field: identification of Vibrio cholerae serogroup O1, serotype Inaba, biotype El Tor strain–Haiti. MMWR Morb Mortal Wkly Rep 61: 309.
  29. Reimer CB, Phillips DJ, Aloisio CH, Moore DD, Galland GG, Wells TW, Black CM, McDougal JS, , 1984. Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma 3: 263275.[Crossref]
  30. Goma Epidemiology Group, 1995. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July 1994. Lancet 345: 339344.[Crossref]
  31. Roberts L, Toole MJ, , 1995. Cholera deaths in Goma. Lancet 346: 1431.[Crossref]
  32. Hartley DM, Morris JG, Jr Smith DL, , 2006. Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics? PLoS Med 3: e7.[Crossref]
  33. Sack DA, Sack RB, Nair GB, Siddique AK, , 2004. Cholera. Lancet 363: 223233.[Crossref]
  34. Roy SK, Hossain MJ, Khatun W, Chakraborty B, Chowdhury S, Begum A, Mah-e-Muneer S, Shafique S, Khanam M, Chowdhury R, , 2008. Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. BMJ 336: 266268.[Crossref]
  35. Glass RI, Svennerholm AM, Stoll BJ, Khan MR, Huda S, Huq MI, Holmgren J, , 1989. Effects of undernutrition on infection with Vibrio cholerae O1 and on response to oral cholera vaccine. Pediatr Infect Dis J 8: 105109.
  36. Palmer DL, Koster FT, Alam AKMJ, Islam MR, , 1976. Nutritional status: a determinant of severity of diarrhea in patients with cholera. J Infect Dis 134: 814.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.13-0208
Loading
/content/journals/10.4269/ajtmh.13-0208
Loading

Data & Media loading...

  • Received : 19 Apr 2013
  • Accepted : 21 Jul 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error